Loss of CELF2 promotes skin tumorigenesis and increases drug resistance
International Journal of Dermatology · 2025
DOI: 10.1111/ijd.17295 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Bindeshwar Sah und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Hormel Institute, University of Minnesota, Austin, MN, USA. Hauptthemen laut MEDLINE: Skin Neoplasms, Carcinoma, Squamous Cell, Drug Resistance, Neoplasm, Cell Proliferation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
CELF2 belongs to the CELF RNA‐binding protein family and exhibits antitumor activity in various tumor models. Analysis of the pan‐cancer TCGA database reveals that CELF2 expression strongly correlates with favorable prognosis among cancer patients. The function of CELF2 in nonmelanoma skin cancer has not been studied.
Methods
We used shRNA‐mediated knockdown (KD) of CELF2 expression in human squamous cell carcinoma (SCC) cells to investigate how CELF2 impacted SCC cell proliferation, survival, and xenograft tumor growth. We determined CELF2 expression in human SCC tissues and adjacent normal skin using immunofluorescence staining. Additionally, we investigated the changes in CELF2 and its target gene expression during UV‐induced and chemical‐induced skin tumorigenesis by western blotting.
Results
CELF2 KD significantly increased SCC cell proliferation, colony growth, and SCC xenograft tumor growth in immunodeficient mice. CELF2 KD in SCC cells led to activation of KRT80 and GDF15, which can potentially promote cell proliferation and tumor growth. While control SCC cells were sensitive to anticancer drugs such as doxorubicin, SCC cells with CELF2 KD became resistant to drug‐induced tumor growth retardation. Finally, we found CELF2 expression diminished during both UV‐ and chemical‐induced skin tumorigenesis in mice, consistent with reduced CELF2 expression in human SCC tumors compared to adjacent normal skin.
Conclusion
This study shows for the first time that CELF2 loss occurs during skin tumorigenesis and increases drug resistance in SCC cells, highlighting the possibility of targeting CELF2‐regulated pathways in skin cancer prevention and therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Hormel Institute, University of Minnesota, Austin, MN, USA.
- Department of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.
- Department of Internal Medicine and Dermatology, University of Minnesota, Minneapolis, MN, USA.
- Minneapolis VA Medical Center Health Care System, Minneapolis, Minnesota, USA.
- Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
ORCID-Profile: Liang Liu
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Sah, B., Singh, J., Shen, Y., Goldfarb, N., Samie, F. H., Geskin, L. J., & Liu, L. (2025). Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. International Journal of Dermatology. https://doi.org/10.1111/ijd.17295
Vancouver
Sah B, Singh J, Shen Y, Goldfarb N, Samie FH, Geskin LJ, et al. Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. International Journal of Dermatology. 2025. doi:10.1111/ijd.17295
BibTeX
@article{Sah2025,
author = {Sah, Bindeshwar and Singh, Jasvinder and Shen, Yao and Goldfarb, Noah and Samie, Faramarz H and Geskin, Larisa J and Liu, Liang},
title = {Loss of CELF2 promotes skin tumorigenesis and increases drug resistance},
journal = {International Journal of Dermatology},
year = {2025},
doi = {10.1111/ijd.17295}
}
EUVIMED